Loading...
NPI 1407517105 · Chicago, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
County Diagnostic Incorporation is a clinical medical laboratory provider located in Chicago, Illinois. This profile covers 1 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | County Diagnostic Incorporation |
| Address | 5129 W Devon Ave |
| City | Chicago |
| State | IL |
| ZIP | 60646 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 5, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.3M |
| Medicaid | $92.8K |
COUNTY DIAGNOSTIC INCORPORATION’s billing profile is concentrated in COVID-19 testing and related specimen services: the Medicare revenue stream is 100% attributable to K1034 (Provision of covid-19 test, nonprescription self-administered and self-collected use), and Medicaid billing is dominated by U0003, 87811, and G2023, which are molecular detection, immunoassay, and specimen collection codes respectively. This code mix indicates the entity operates as a clinical testing/laboratory service focused on SARS‑CoV‑2 diagnostics and distribution of nonprescription self-tests rather than a broad outpatient lab portfolio.
Medicare revenue is effectively single-code driven: K1034 accounts for $5.3M and represents 100.0% of the provider’s total Medicare revenue, with 443K claims and an average paid/claim of $12. This K1034 volume ranks #88 of 30143 providers nationally and is labeled an extreme outlier (100th percentile), indicating unusually high national activity on that specific code.
Medicaid revenue is smaller in scale and concentrated but slightly more diversified: total Medicaid revenue is $92.8K and the top three Medicaid codes (U0003, 87811, G2023) together account for 86.5% of that Medicaid revenue. Specifically, U0003 contributes $45.8K (49.4%), 87811 contributes $20K (21.6%), and G2023 contributes $14.4K (15.5%), showing a mix of high-throughput molecular testing and point-of-care immunoassay services.
The provider’s payer mix is heavily Medicare-weighted: Medicare revenue of $5.3M dwarfs Medicaid revenue of $92.8K, making this an operation that is effectively Medicare-driven in scale. Analysts should treat this entity as a Medicare-centric testing provider for strategic or capacity comparisons rather than a Medicaid-focused lab.
Competitive standing differs dramatically between payers: for the Medicare-dominant K1034 the provider is a national outlier (rank #88/30143, extreme outlier at the 100th percentile), signaling a dominant presence for that specific service at the national level. By contrast, in-state Medicaid ranks for the leading codes are near the middle of their peer groups (U0003: #162/350, 54th percentile; 87811: #183/548, 67th percentile; G2023: #187/396, 53th percentile), which indicates ordinary, typical in-state participation rather than market dominance on those Medicaid services.
Operational and margin implications are visible in the per-claim payments and volume mix: the Medicare K1034 activity shows very high volume (443K claims) with a modest average paid/claim of $12, consistent with distribution or processing of low-margin, high-throughput nonprescription COVID tests. Medicaid payments show higher per-claim averages for molecular methods (e.g., U0003 at $74 avg paid/claim) alongside immunoassay and collection fees, reflecting a mix of test modalities and revenue-per-test profiles across payers.
Tenure and concentration risk should be noted: the provider’s NPI was enumerated on 2022-01-05 (~4 years ago), and its current revenues are heavily tied to pandemic-era testing codes. This profile suggests potential revenue volatility if demand, reimbursement policy, or coding guidance for COVID-19 testing changes, because Medicare revenue is nearly entirely concentrated in K1034 and Medicaid revenue is 86.5% concentrated among three COVID-related codes.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 443,040 | $10 | $5.3M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 26 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 620 | $70 | $45.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 500 | $40 | $20K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 630 | $20 | $14.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 470 | $20 | $11.2K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 660 | $1 | $1.3K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 162 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 116 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 187 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 183 | 550 | 240 | $40 | $42.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 30 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as County Diagnostic Incorporation, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Rainbow Lab Inc | IL | Clinical Medical Laboratory | $15.1M | $9.7M |
| S K Diagnostics Inc | IL | Clinical Medical Laboratory | $21.4M | $20.3K |
| Az Labs Limited | IL | Clinical Medical Laboratory | $12.8M | $255.6K |
| Cl Labs Inc. | IL | Clinical Medical Laboratory | $166.5K | $11M |
| Safeena Enterprises Inc | IL | Clinical Medical Laboratory | $8.6M | $0 |
| Chicago Department Of Public Health | IL | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $6.2M |
| Aza Labs Inc | IL | Clinical Medical Laboratory | $1M | $5M |
| Abdulmassih Abdulmassih | IL | Family Medicine Physician | $374.7K | $3.3M |
| Kyriaki Ades | IL | Dentist | $0 | $3.6M |
| Aim One Incorporated | IL | Durable Medical Equipment & Medical Supplies | $0 | $3.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.